CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Cannabidiol 400 +2 moredrug
Likely dose
Cannabidiol 400 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01605539
NCT01605539Phase 2Completed
CompareCT.gov

Cannabidiol as Treatment Intervention for Opioid Relapse

Hurd,Yasmin, Ph.D.·interventional·Posted May 25, 2012·Updated Aug 11, 2020

In Brief

A Phase 2 clinical trial evaluating Cannabidiol 400, Cannabidiol 800, and 1 other intervention for Opiate Addiction. Completed, enrolled 10 participants across 1 site.

Detailed Summary

Despite the current available therapies for opioid-dependent patients, most patients relapse. This research project focuses on the development of a novel compound, cannabidiol, to modulate opioid craving in humans based on animal models showing its selective effectiveness to inhibit drug-seeking behavior. The development of a targeted treatment for opioid relapse would be of tremendous medical and public health value.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpiate Addiction
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 25, 2012
Enrollment StartMay 1, 2012
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 14.1 years ago

Interventions

Cannabidiol 400drug

Subjects in Arm CBD 400 will receive 400mg of Cannabidiol in each of the three test sessions

Cannabidiol 800drug

Subjects in Arm CBD 800 will receive 800mg of Cannabidiol in each of the three test sessions

Controldrug

Subjects will receive a harmless, inactive pill to compare and validate the results of the other arms of the study